Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A rare HIV reverse transcriptase mutation, K65N, confers reduced susceptibility to tenofovir, lamivudine and didanosine.

AIDS (London, England) - 21 Mar 2006

Ross Lisa L, Dretler Robin, Gerondelis Peter, Rouse Elizabeth G, Lim Michael L, Lanier Ernest R

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiretroviral Therapy, Highly Active
Share to Drug Resistance, Viral
Share to HIV-1
Share to HIV Infections

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Reverse Transcriptase

Share to Mutation

Share to Reverse Transcriptase Inhibitors

Source

Identifiers

PMID: 16514317
DOI: 10.1097/01.aids.0000216387.60481.0e

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A rare HIV reverse transcriptase mutation, K65N, confers reduced susceptibility to tenofovir, lamivudine and didanosine.PMID 16514317Read ↗

The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients.Semantic proximity Read ↗

The K65R Mutation in HIV-1 Reverse Transcriptase: Genetic Barriers, Resistance Profile and Clinical ImplicationsSemantic proximity Read ↗

Clinical and genotypic correlates of mutation K65R in HIV-infected patients failing regimens not including tenofovir.Semantic proximity Read ↗

K65R, TAMs and tenofovir.Semantic proximity Read ↗

Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir.Semantic proximity Read ↗

K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine.Semantic proximity Read ↗

Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine.Semantic proximity Read ↗

Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria.Semantic proximity Read ↗

The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations.Semantic proximity Read ↗

K65R-associated virologic failure in HIV-infected patients receiving tenofovir-containing triple nucleoside/nucleotide reverse transcriptase inhibitor regimens.Semantic proximity Read ↗

Predictors of selection of K65R: tenofovir use and lack of thymidine analogue mutations.Semantic proximity Read ↗

The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.